NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free LUNG Stock Alerts $7.30 -0.22 (-2.93%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$7.11▼$7.4250-Day Range$7.30▼$14.5052-Week Range$7.11▼$14.84Volume196,298 shsAverage Volume500,434 shsMarket Capitalization$281.34 millionP/E RatioN/ADividend YieldN/APrice Target$15.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Pulmonx alerts: Email Address Pulmonx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside116.9% Upside$15.83 Price TargetShort InterestHealthy4.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 4 Articles This WeekInsider TradingSelling Shares$469,012 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.79) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.25 out of 5 starsMedical Sector507th out of 908 stocksSurgical & Medical Instruments Industry57th out of 96 stocks 3.4 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePulmonx has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.95% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently increased by 53.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 1.4 News and Social Media Coverage News SentimentPulmonx has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pulmonx this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $469,012.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.79) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Pulmonx Stock (NASDAQ:LUNG)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More LUNG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Stock News HeadlinesMarch 27, 2024 | insidertrades.comInsider Selling: Pulmonx Co. (NASDAQ:LUNG) Insider Sells 1,184 Shares of StockApril 25, 2024 | finance.yahoo.comPulmonx Corporation (LUNG) Stock Price, News, Quote & History - Yahoo FinanceApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 24, 2024 | americanbankingnews.comPulmonx (LUNG) to Release Earnings on WednesdayApril 10, 2024 | globenewswire.comPulmonx to Report First Quarter 2024 Financial Results on May 1, 2024April 4, 2024 | investing.comPulmonx names new CFO to bolster financial leadershipApril 3, 2024 | markets.businessinsider.comNavigating 6 Analyst Ratings For PulmonxApril 2, 2024 | marketwatch.comPulmonx Taps Mehul Joshi as Finance ChiefApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 2, 2024 | globenewswire.comPulmonx Announces Appointment of Mehul Joshi as Chief Financial OfficerMarch 17, 2024 | ca.finance.yahoo.comLUNG Apr 2024 12.500 callMarch 16, 2024 | finanznachrichten.dePulmonx Corporation: Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 15, 2024 | globenewswire.comPulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | ca.finance.yahoo.comLUNG Apr 2024 7.500 putMarch 4, 2024 | ca.finance.yahoo.comLUNG May 2024 7.500 putMarch 3, 2024 | finance.yahoo.comLUNG Aug 2024 10.000 putMarch 3, 2024 | finance.yahoo.comLUNG Apr 2024 10.000 callMarch 3, 2024 | finance.yahoo.comLUNG Aug 2024 20.000 callMarch 1, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Bolsters Position in Pulmonx CorpFebruary 26, 2024 | finanznachrichten.dePulmonx Corporation: Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal TrialFebruary 26, 2024 | businesswire.comPulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal TrialFebruary 25, 2024 | msn.comPulmonx (LUNG) Price Target Increased by 7.61% to 16.83February 24, 2024 | finance.yahoo.comUS$16.50 - That's What Analysts Think Pulmonx Corporation (NASDAQ:LUNG) Is Worth After These ResultsFebruary 23, 2024 | msn.comWells Fargo Downgrades Pulmonx (LUNG)February 23, 2024 | msn.comPulmonx dips on Wells Fargo downgrade eyeing uncertainty over management changesFebruary 23, 2024 | finance.yahoo.comPulmonx Full Year 2023 Earnings: Beats ExpectationsFebruary 23, 2024 | realmoney.thestreet.comWells Fargo downgrades Pulmonx on management uncertaintySee More Headlines Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/25/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees279Year FoundedN/APrice Target and Rating Average Stock Price Target$15.83 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+116.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,840,000.00 Net Margins-88.60% Pretax Margin-87.76% Return on Equity-46.63% Return on Assets-32.14% Debt Debt-to-Equity Ratio0.30 Current Ratio6.50 Quick Ratio5.77 Sales & Book Value Annual Sales$68.68 million Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book2.36Miscellaneous Outstanding Shares38,540,000Free Float36,340,000Market Cap$281.34 million OptionableOptionable Beta0.60 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David A. Lehman (Age 63)General Counsel & Secretary Comp: $651.39kMr. Geoffrey Beran Rose (Age 50)Chief Commercial Officer Comp: $632.29kMr. Steven S. Williamson (Age 51)CEO, President & Director Mr. Mehul Joshi (Age 63)Chief Financial Officer Mr. Sri RadhakrishnanChief Technical OfficerMs. Marcee M. Maroney (Age 54)Vice President of Marketing Sarah HuberVice President of Sales (U.S.)Ms. Lisa Paul (Age 60)Chief People Officer Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaMr. John B. McKune (Age 48)VP & Corporate Controller More ExecutivesKey CompetitorsSight SciencesNASDAQ:SGHTCerusNASDAQ:CERSCVRxNASDAQ:CVRXLyra TherapeuticsNASDAQ:LYRAFractyl HealthNASDAQ:GUTSView All CompetitorsInsiders & InstitutionsGeoffrey Beran RoseSold 1,184 sharesTotal: $8,868.16 ($7.49/share)Allspring Global Investments Holdings LLCBought 7,316 shares on 4/18/2024Ownership: 0.022%Geoffrey Beran RoseSold 1,184 sharesTotal: $11,082.24 ($9.36/share)Glendon E French IIISold 6,954 sharesTotal: $63,003.24 ($9.06/share)Geoffrey Beran RoseSold 3,097 sharesTotal: $28,058.82 ($9.06/share)View All Insider TransactionsView All Institutional Transactions LUNG Stock Analysis - Frequently Asked Questions Should I buy or sell Pulmonx stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LUNG shares. View LUNG analyst ratings or view top-rated stocks. What is Pulmonx's stock price target for 2024? 6 equities research analysts have issued 1 year target prices for Pulmonx's stock. Their LUNG share price targets range from $12.00 to $18.00. On average, they predict the company's stock price to reach $15.83 in the next year. This suggests a possible upside of 116.9% from the stock's current price. View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts. How have LUNG shares performed in 2024? Pulmonx's stock was trading at $12.75 on January 1st, 2024. Since then, LUNG shares have decreased by 42.7% and is now trading at $7.30. View the best growth stocks for 2024 here. Are investors shorting Pulmonx? Pulmonx saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,730,000 shares, an increase of 53.1% from the March 31st total of 1,130,000 shares. Based on an average daily volume of 557,800 shares, the short-interest ratio is presently 3.1 days. Approximately 5.0% of the shares of the company are short sold. View Pulmonx's Short Interest. When is Pulmonx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our LUNG earnings forecast. How can I listen to Pulmonx's earnings call? Pulmonx will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) posted its earnings results on Wednesday, February, 21st. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.02. The company had revenue of $19.30 million for the quarter, compared to analyst estimates of $18.24 million. Pulmonx had a negative trailing twelve-month return on equity of 46.63% and a negative net margin of 88.60%. Pulmonx's revenue was up 25.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.38) EPS. What guidance has Pulmonx issued on next quarter's earnings? Pulmonx updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $78.9 million. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, John Mckune, Richard Ferrari and Scientific Corp Boston. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUNG) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
